Stock Analysis on Net

Zoetis Inc. (NYSE:ZTS)

This company has been moved to the archive! The financial data has not been updated since May 2, 2024.

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

Zoetis Inc., historical price multiples (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Price to earnings (P/E) 31.91 35.84 32.40 39.38 39.82 37.68 29.57 39.04 38.92 45.82 51.98 50.61 44.83 48.25 48.84 47.41 37.05 45.89
Price to operating profit (P/OP) 24.57 27.86 24.60 29.66 29.07 27.31 21.67 28.91 28.81 33.82 38.47 36.90 32.33 35.22 36.65 36.24 28.78 35.00
Price to sales (P/S) 8.74 9.83 8.83 10.60 10.19 9.86 7.63 10.21 10.23 12.00 13.53 13.03 11.34 11.84 12.42 12.09 9.42 11.00
Price to book value (P/BV) 15.09 16.81 14.55 18.84 18.35 18.08 13.11 17.82 17.32 20.55 22.02 22.21 19.45 20.97 22.55 25.71 21.68 25.42 21.53 24.00 21.31

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Zoetis Inc. P/E ratio increased from Q3 2023 to Q4 2023 but then decreased significantly from Q4 2023 to Q1 2024.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Zoetis Inc. P/OP ratio increased from Q3 2023 to Q4 2023 but then decreased significantly from Q4 2023 to Q1 2024.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Zoetis Inc. P/S ratio increased from Q3 2023 to Q4 2023 but then decreased significantly from Q4 2023 to Q1 2024.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Zoetis Inc. P/BV ratio increased from Q3 2023 to Q4 2023 but then slightly decreased from Q4 2023 to Q1 2024 not reaching Q3 2023 level.

Price to Earnings (P/E)

Zoetis Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
No. shares of common stock outstanding1 456,295,137 457,867,115 459,113,691 460,316,905 462,112,140 463,386,716 466,071,995 468,138,568 470,628,655 471,970,580 473,125,822 473,944,193 474,766,701 475,166,373 475,267,819 475,144,704 474,940,772 474,933,945 476,299,250 477,557,942 478,656,189
Selected Financial Data (US$)
Net income attributable to Zoetis Inc. (in millions) 599 525 596 671 552 461 529 529 595 414 552 512 559 359 479 377 423 384 433 371 312
Earnings per share (EPS)2 5.24 5.12 4.97 4.81 4.48 4.56 4.43 4.46 4.40 4.32 4.19 4.03 3.74 3.45 3.50 3.40 3.39 3.16 0.00 0.00 0.00
Share price1, 3 167.23 183.49 160.91 189.30 178.47 171.90 131.14 174.31 171.45 197.76 217.77 203.84 167.52 166.32 170.90 161.33 125.69 144.94 121.03 121.17 103.15
Valuation Ratio
P/E ratio4 31.91 35.84 32.40 39.38 39.82 37.68 29.57 39.04 38.92 45.82 51.98 50.61 44.83 48.25 48.84 47.41 37.05 45.89
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. 48.26 63.84 38.27 30.55 34.43 22.62 19.16 19.44 21.64 22.07 27.34 30.62 39.63 40.17
Amgen Inc. 44.38 23.14 18.09 16.31 16.18 19.56 21.00 20.03 22.23 21.05 21.91 22.56 19.20 18.82
Bristol-Myers Squibb Co. 12.27 13.01 15.93 19.43 23.97 23.71 24.14 25.64 20.92
Danaher Corp. 42.59 39.09 24.76 29.99 25.00 25.65 26.65 32.73 32.15 29.94 38.81 37.87 39.26 44.49
Eli Lilly & Co. 120.94 135.24 110.43 76.21 65.16 50.08 55.53 51.05 45.29 40.66 40.07 40.34 28.77 31.95
Gilead Sciences Inc. 166.76 16.17 17.10 17.88 17.75 22.68 29.30 18.66 17.25 12.36 11.44 16.83 277.25 641.48
Johnson & Johnson 9.46 10.73 10.12 33.35 33.43 22.97 23.52 24.98 23.95 20.93 23.98 25.51 28.35 28.92
Merck & Co. Inc. 140.05 893.99 56.85 86.53 22.92 19.21 16.41 13.36 15.70 14.78 28.65 34.23 28.00 26.72
Pfizer Inc. 73.42 16.60 9.42 7.44 7.58 8.81 9.56 11.11 11.76 14.03 20.05 20.15 19.62
Regeneron Pharmaceuticals Inc. 26.78 25.99 22.35 19.48 19.77 19.68 14.98 11.67 9.15 8.37 9.96 10.38 13.27 15.09
Thermo Fisher Scientific Inc. 36.21 35.65 29.57 37.01 34.99 30.55 27.64 31.09 28.15 27.35 29.43 24.63 23.23 27.89
Vertex Pharmaceuticals Inc. 26.34 30.42 28.09 27.49 27.34 23.02 24.62 23.12 26.50 26.55 22.09 26.26 20.45 20.18

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Data adjusted for splits and stock dividends.

2 Q1 2024 Calculation
EPS = (Net income attributable to Zoetis Inc.Q1 2024 + Net income attributable to Zoetis Inc.Q4 2023 + Net income attributable to Zoetis Inc.Q3 2023 + Net income attributable to Zoetis Inc.Q2 2023) ÷ No. shares of common stock outstanding
= (599,000,000 + 525,000,000 + 596,000,000 + 671,000,000) ÷ 456,295,137 = 5.24

3 Closing price as at the filing date of Zoetis Inc. Quarterly or Annual Report.

4 Q1 2024 Calculation
P/E ratio = Share price ÷ EPS
= 167.23 ÷ 5.24 = 31.91

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Zoetis Inc. P/E ratio increased from Q3 2023 to Q4 2023 but then decreased significantly from Q4 2023 to Q1 2024.

Price to Operating Profit (P/OP)

Zoetis Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
No. shares of common stock outstanding1 456,295,137 457,867,115 459,113,691 460,316,905 462,112,140 463,386,716 466,071,995 468,138,568 470,628,655 471,970,580 473,125,822 473,944,193 474,766,701 475,166,373 475,267,819 475,144,704 474,940,772 474,933,945 476,299,250 477,557,942 478,656,189
Selected Financial Data (US$)
Operating income (in millions) 797 701 782 826 707 688 717 725 787 592 719 703 746 510 659 545 530 482 558 504 423
Operating profit per share2 6.81 6.59 6.54 6.38 6.14 6.29 6.05 6.03 5.95 5.85 5.66 5.52 5.18 4.72 4.66 4.45 4.37 4.14 0.00 0.00 0.00
Share price1, 3 167.23 183.49 160.91 189.30 178.47 171.90 131.14 174.31 171.45 197.76 217.77 203.84 167.52 166.32 170.90 161.33 125.69 144.94 121.03 121.17 103.15
Valuation Ratio
P/OP ratio4 24.57 27.86 24.60 29.66 29.07 27.31 21.67 28.91 28.81 33.82 38.47 36.90 32.33 35.22 36.65 36.24 28.78 35.00
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. 22.62 24.34 16.55 15.26 16.15 14.78 14.52 14.12 14.57 14.21 12.41 13.12 17.23 16.32
Amgen Inc. 23.97 19.69 15.45 13.71 14.25 13.40 14.89 14.08 15.88 16.24 16.73 17.48 15.26 14.96
Bristol-Myers Squibb Co. 13.53 14.14 16.24 17.09 18.29 17.79 18.62 20.32 19.84
Danaher Corp. 37.52 35.64 23.61 27.01 21.31 20.97 20.71 25.91 26.48 25.14 32.12 30.83 32.62 36.91
Eli Lilly & Co. 99.34 109.75 93.27 69.42 59.60 43.88 46.48 39.20 36.49 35.70 37.21 42.01 31.17 32.66
Gilead Sciences Inc. 51.26 12.05 12.16 11.57 11.21 14.21 16.27 11.02 10.78 7.76 7.27 8.88 18.31 19.38
Johnson & Johnson 16.96 17.78 15.69 18.91 18.26 17.62 19.64 20.45 21.06 18.68 18.99 20.14 21.12 21.84
Merck & Co. Inc. 75.94 138.56 33.75 44.67 18.53 15.55 13.85 11.72 14.29 15.39 30.71 38.03 30.14 23.89
Pfizer Inc. 121.63 17.49 9.17 6.74 6.80 7.82 9.11 11.49 13.30 16.37 19.83 22.85 23.12
Regeneron Pharmaceuticals Inc. 26.82 25.39 21.13 19.32 18.68 18.01 12.91 9.68 7.98 7.55 9.32 9.65 13.32 14.82
Thermo Fisher Scientific Inc. 31.40 31.16 25.59 31.55 29.54 25.30 21.43 23.99 21.84 21.07 23.87 19.77 18.53 22.81
Vertex Pharmaceuticals Inc. 25.25 28.74 25.14 23.33 22.03 17.75 19.41 18.11 22.13 22.35 18.14 23.06 18.68 19.16

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Data adjusted for splits and stock dividends.

2 Q1 2024 Calculation
Operating profit per share = (Operating incomeQ1 2024 + Operating incomeQ4 2023 + Operating incomeQ3 2023 + Operating incomeQ2 2023) ÷ No. shares of common stock outstanding
= (797,000,000 + 701,000,000 + 782,000,000 + 826,000,000) ÷ 456,295,137 = 6.81

3 Closing price as at the filing date of Zoetis Inc. Quarterly or Annual Report.

4 Q1 2024 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 167.23 ÷ 6.81 = 24.57

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Zoetis Inc. P/OP ratio increased from Q3 2023 to Q4 2023 but then decreased significantly from Q4 2023 to Q1 2024.

Price to Sales (P/S)

Zoetis Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
No. shares of common stock outstanding1 456,295,137 457,867,115 459,113,691 460,316,905 462,112,140 463,386,716 466,071,995 468,138,568 470,628,655 471,970,580 473,125,822 473,944,193 474,766,701 475,166,373 475,267,819 475,144,704 474,940,772 474,933,945 476,299,250 477,557,942 478,656,189
Selected Financial Data (US$)
Revenue (in millions) 2,190 2,213 2,151 2,180 2,000 2,040 2,002 2,052 1,986 1,967 1,990 1,948 1,871 1,807 1,786 1,548 1,534 1,674 1,584 1,547 1,455
Sales per share2 19.14 18.66 18.23 17.86 17.52 17.44 17.18 17.08 16.77 16.48 16.10 15.64 14.77 14.05 13.76 13.34 13.35 13.18 0.00 0.00 0.00
Share price1, 3 167.23 183.49 160.91 189.30 178.47 171.90 131.14 174.31 171.45 197.76 217.77 203.84 167.52 166.32 170.90 161.33 125.69 144.94 121.03 121.17 103.15
Valuation Ratio
P/S ratio4 8.74 9.83 8.83 10.60 10.19 9.86 7.63 10.21 10.23 12.00 13.53 13.03 11.34 11.84 12.42 12.09 9.42 11.00
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. 5.32 5.72 4.52 4.74 4.60 4.61 4.44 4.28 4.76 4.53 3.73 3.80 4.07 4.05
Amgen Inc. 5.93 5.78 5.34 5.14 5.14 5.17 5.85 5.35 5.21 5.10 5.04 5.37 5.68 5.64
Bristol-Myers Squibb Co. 1.99 2.19 2.40 2.81 3.10 3.29 3.39 3.39 3.41 3.16 2.85 3.44 3.28 3.16
Danaher Corp. 7.90 7.76 5.63 6.77 5.76 5.79 5.66 6.59 6.68 6.37 7.91 7.72 7.27 7.01
Eli Lilly & Co. 20.66 20.77 17.18 16.78 13.38 10.96 11.46 9.99 9.47 8.01 8.62 9.16 6.88 8.06
Gilead Sciences Inc. 2.97 3.40 3.69 3.61 3.70 3.86 3.64 2.84 2.86 2.85 3.11 3.30 3.31 3.24
Johnson & Johnson 4.25 4.43 4.01 4.84 4.60 4.34 4.69 4.80 5.00 4.66 4.69 5.08 5.09 5.15
Merck & Co. Inc. 5.26 5.43 4.42 4.62 5.16 4.71 4.25 3.87 4.12 3.96 4.32 4.05 4.23 3.93
Pfizer Inc. 2.86 2.61 2.51 2.58 2.32 2.37 2.63 2.77 3.00 3.18 4.04 4.78 4.84 4.50
Regeneron Pharmaceuticals Inc. 7.89 7.84 6.81 6.61 6.69 7.01 5.87 4.66 4.40 4.20 5.14 5.20 5.78 6.24
Thermo Fisher Scientific Inc. 5.14 4.99 4.05 4.87 4.81 4.73 4.40 5.40 5.20 5.39 6.45 5.54 5.13 5.52
Vertex Pharmaceuticals Inc. 10.39 11.16 10.10 9.73 9.68 8.56 9.26 8.85 8.17 8.21 6.74 7.82 8.81 8.82

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Data adjusted for splits and stock dividends.

2 Q1 2024 Calculation
Sales per share = (RevenueQ1 2024 + RevenueQ4 2023 + RevenueQ3 2023 + RevenueQ2 2023) ÷ No. shares of common stock outstanding
= (2,190,000,000 + 2,213,000,000 + 2,151,000,000 + 2,180,000,000) ÷ 456,295,137 = 19.14

3 Closing price as at the filing date of Zoetis Inc. Quarterly or Annual Report.

4 Q1 2024 Calculation
P/S ratio = Share price ÷ Sales per share
= 167.23 ÷ 19.14 = 8.74

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Zoetis Inc. P/S ratio increased from Q3 2023 to Q4 2023 but then decreased significantly from Q4 2023 to Q1 2024.

Price to Book Value (P/BV)

Zoetis Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
No. shares of common stock outstanding1 456,295,137 457,867,115 459,113,691 460,316,905 462,112,140 463,386,716 466,071,995 468,138,568 470,628,655 471,970,580 473,125,822 473,944,193 474,766,701 475,166,373 475,267,819 475,144,704 474,940,772 474,933,945 476,299,250 477,557,942 478,656,189
Selected Financial Data (US$)
Total Zoetis Inc. equity (in millions) 5,058 4,997 5,078 4,625 4,494 4,405 4,663 4,580 4,658 4,543 4,679 4,350 4,089 3,769 3,602 2,982 2,753 2,708 2,678 2,411 2,317
Book value per share (BVPS)2 11.08 10.91 11.06 10.05 9.72 9.51 10.00 9.78 9.90 9.63 9.89 9.18 8.61 7.93 7.58 6.28 5.80 5.70 5.62 5.05 4.84
Share price1, 3 167.23 183.49 160.91 189.30 178.47 171.90 131.14 174.31 171.45 197.76 217.77 203.84 167.52 166.32 170.90 161.33 125.69 144.94 121.03 121.17 103.15
Valuation Ratio
P/BV ratio4 15.09 16.81 14.55 18.84 18.35 18.08 13.11 17.82 17.32 20.55 22.02 22.21 19.45 20.97 22.55 25.71 21.68 25.42 21.53 24.00 21.31
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. 36.12 29.97 20.61 20.62 19.68 15.52 16.06 16.76 16.59 16.53 15.20 16.23 14.91 14.18 10.93 11.31
Amgen Inc. 33.25 24.94 17.87 19.19 23.95 35.01 39.30 54.46 138.87 18.51 14.95 15.72 14.57 14.53 11.57 13.67 14.33
Bristol-Myers Squibb Co. 5.49 3.35 3.72 3.97 4.46 4.88 4.85 4.90 5.07 4.07 3.48 4.15 3.73 3.55 2.87 2.82 2.77
Danaher Corp. 3.51 3.47 2.78 3.65 3.33 3.64 3.77 4.36 4.36 4.16 5.11 4.82 4.46 3.93 4.38 3.90 3.68
Eli Lilly & Co. 57.94 65.80 49.10 44.75 33.11 29.36 33.27 34.00 29.75 25.28 30.85 38.00 25.41 35.07 26.02 35.12 47.73
Gilead Sciences Inc. 4.61 4.01 4.50 4.63 4.72 4.90 4.63 3.82 3.91 3.65 3.94 4.41 4.40 4.33 4.30 4.79 4.40
Johnson & Johnson 5.20 5.48 4.92 5.79 6.00 5.37 6.04 6.01 6.36 5.90 6.10 6.51 6.51 6.72 5.93 6.19 6.46
Merck & Co. Inc. 8.00 8.68 6.35 6.96 6.38 6.07 5.63 5.12 5.44 5.05 5.76 5.73 7.30 7.46 6.97 7.47 7.43
Pfizer Inc. 1.74 1.75 1.80 2.04 2.14 2.48 2.83 3.21 3.37 3.35 3.69 3.78 3.27 2.98 3.10 3.31 3.16
Regeneron Pharmaceuticals Inc. 3.83 3.96 3.58 3.49 3.52 3.77 3.75 3.21 3.65 3.60 4.04 4.26 4.44 4.81 6.21 7.34 5.33
Thermo Fisher Scientific Inc. 4.80 4.57 3.88 4.84 4.99 4.83 4.46 5.47 5.23 5.18 6.51 5.75 5.25 5.15 5.89 5.48 4.56
Vertex Pharmaceuticals Inc. 5.71 6.26 5.90 5.98 6.18 5.50 6.18 6.19 5.95 6.16 5.04 5.69 6.29 6.30 6.66 9.42 10.23

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Data adjusted for splits and stock dividends.

2 Q1 2024 Calculation
BVPS = Total Zoetis Inc. equity ÷ No. shares of common stock outstanding
= 5,058,000,000 ÷ 456,295,137 = 11.08

3 Closing price as at the filing date of Zoetis Inc. Quarterly or Annual Report.

4 Q1 2024 Calculation
P/BV ratio = Share price ÷ BVPS
= 167.23 ÷ 11.08 = 15.09

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Zoetis Inc. P/BV ratio increased from Q3 2023 to Q4 2023 but then slightly decreased from Q4 2023 to Q1 2024 not reaching Q3 2023 level.